PharmacoEconomics

Keyphrases

Publications

volume 42, number 9, 2024

Caique de Melo do Espirito Santo, Gisela Cristiane Miyamoto, Verônica Souza Santos, Ângela Jornada Ben, Aureliano Paolo Finch, Bram Roudijk, Fabianna Resende Jesus Moraleida, Airton Tetelbom Stein, Marisa da Silva Santos, Tiê Parma Yamato
Estimating an EQ-5D-Y-3L Value Set for Brazil. PharmacoEconomics 42 (9) (2024)
Ni Gao, Helen A Dakin, Rury R Holman, Lee-Ling Lim, José Leal, Philip Clarke
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management. PharmacoEconomics 42 (9) (2024)
Lisa Aniek de Jong, Xinyu Li, Sajad Emamipour, Sjoukje van der Werf, Maarten J Postma, Peter Ruben van Dijk, Talitha L Feenstra
Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data. PharmacoEconomics 42 (9) (2024)
Andrew John Sutton, Daniel S Lupu, Stephen P Bergin, Thomas L Holland, Staci A McAdams, Sanjeet Singh Dadwal, Khoi Nguyen, Frederick S Nolte, Gabriel Tremblay, Bradley A Perkins
Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host Pneumonia. PharmacoEconomics 42 (9) (2024)
Andreas Freitag, Grammati Sarri, An Ta, Laura Gurskyte, Dasha Cherepanov, Luis G Hernandez
A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models. PharmacoEconomics 42 (9) (2024)
Andreas Freitag, Grammati Sarri, An Ta, Laura Gurskyte, Dasha Cherepanov, Luis G Hernandez
A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models. PharmacoEconomics 42 (9) (2024)
Ni Gao, Helen A Dakin, Rury R Holman, Lee-Ling Lim, José Leal, Philip Clarke
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management. PharmacoEconomics 42 (9) (2024)
Lisa Aniek de Jong, Xinyu Li, Sajad Emamipour, Sjoukje van der Werf, Maarten J Postma, Peter Ruben van Dijk, Talitha L Feenstra
Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data. PharmacoEconomics 42 (9) (2024)
David Glynn, Vijay Singh Gc, Karl Claxton, Chris Littlewood, Claire Rothery
Rapid Assessment of the Need for Evidence: Applying the Principles of Value of Information to Research Prioritisation. PharmacoEconomics 42 (9) (2024)
Sajjad Moradi, Nicole O'Connor, Katie H Thomson, Hossein Shabaninejad, Tumi Sotire, Madeleine Still, Cristina Fernandez-Garcia, Sheila A Wallace, Oleta Williams, Luke Vale, Gurdeep Singh Sagoo
NICE Approaches to Expert Opinion Evidence in Highly Specialised Technologies: Time to Change? Evidence Assessment Group Perspective. PharmacoEconomics 42 (9) (2024)
Paul Tappenden, Orla Hardiman, Sun-Hong Kwon, Mon Mon-Yee, Miriam Galvin, Christopher J McDermott, null null
A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies. PharmacoEconomics 42 (9) (2024)

volume 42, number Suppl 1, 2024

Rachel O'Loughlin, Renee Jones, Gang Chen, Brendan J Mulhern, Harriet Hiscock, Nancy J Devlin, Kim Dalziel, null null
Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression. PharmacoEconomics 42 (Suppl 1) (2024)
Diana Khanna, Jyoti Khadka, Christine Mpundu-Kaambwa, Gang Chen, Kim Dalziel, Nancy J Devlin, Julie Ratcliffe, null null
An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L. PharmacoEconomics 42 (Suppl 1) (2024)
Xiuqin Xiong, Natalie Carvalho, Li Huang, Gang Chen, Renee Jones, Nancy Devlin, Brendan Mulhern, Kim Dalziel
Psychometric Properties of Child Health Utility 9D (CHU9D) Proxy Version Administered to Parents and Caregivers of Children Aged 2-4 Years Compared with Pediatric Quality of Life Inventory™ (PedsQL). PharmacoEconomics 42 (Suppl 1) (2024)
Cate M Bailey, Kim Dalziel, Renee Jones, Harriet Hiscock, Nancy J Devlin, Tessa Peasgood, null null
The Validity of the EuroQol Health and Wellbeing Short Version (EQ-HWB-S) Instrument in Parents of Children With and Without Health Conditions. PharmacoEconomics 42 (Suppl 1) (2024)
Wendy J Ungar, Michael Herdman
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children. PharmacoEconomics 42 (Suppl 1) (2024)
Rachel O'Loughlin, Renee Jones, Gang Chen, Brendan J Mulhern, Harriet Hiscock, Nancy J Devlin, Kim Dalziel, null null
Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression. PharmacoEconomics 42 (Suppl 1) (2024)
Alexander van Heusden, Oliver Rivero-Arias, Michael Herdman, Harriet Hiscock, Nancy J Devlin, Kim Dalziel, null null
Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds. PharmacoEconomics 42 (Suppl 1) (2024)
Christine Mpundu-Kaambwa, Norma B Bulamu, Lauren Elizabeth Lines, Gang Chen, David G T Whitehurst, Kim Dalziel, Nancy J Devlin, Julie Ratcliffe, null null
Exploring the Use of Pictorial Approaches in the Development of Paediatric Patient-Reported Outcome Instruments: A Systematic Review. PharmacoEconomics 42 (Suppl 1) (2024)
Wendy J Ungar, Michael Herdman
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children. PharmacoEconomics 42 (Suppl 1) (2024)
Xiuqin Xiong, Natalie Carvalho, Li Huang, Gang Chen, Renee Jones, Nancy Devlin, Brendan Mulhern, Kim Dalziel
Psychometric Properties of Child Health Utility 9D (CHU9D) Proxy Version Administered to Parents and Caregivers of Children Aged 2-4 Years Compared with Pediatric Quality of Life Inventory™ (PedsQL). PharmacoEconomics 42 (Suppl 1) (2024)
Cate M Bailey, Kim Dalziel, Renee Jones, Harriet Hiscock, Nancy J Devlin, Tessa Peasgood, null null
The Validity of the EuroQol Health and Wellbeing Short Version (EQ-HWB-S) Instrument in Parents of Children With and Without Health Conditions. PharmacoEconomics 42 (Suppl 1) (2024)
Mina Bahrampour, Nancy J Devlin, Renee Jones, Kim Dalziel, Brendan J Mulhern, null null
A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Using Paediatric Multi-Instrument Comparison (P-MIC) Study Data. PharmacoEconomics 42 (Suppl 1) (2024)
Diana Khanna, Jyoti Khadka, Christine Mpundu-Kaambwa, Gang Chen, Kim Dalziel, Nancy J Devlin, Julie Ratcliffe, null null
An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L. PharmacoEconomics 42 (Suppl 1) (2024)
Christine Mpundu-Kaambwa, Norma B Bulamu, Lauren Elizabeth Lines, Gang Chen, David G T Whitehurst, Kim Dalziel, Nancy J Devlin, Julie Ratcliffe, null null
Exploring the Use of Pictorial Approaches in the Development of Paediatric Patient-Reported Outcome Instruments: A Systematic Review. PharmacoEconomics 42 (Suppl 1) (2024)
Xiuqin Xiong, Natalie Carvalho, Li Huang, Gang Chen, Renee Jones, Nancy Devlin, Brendan Mulhern, Kim Dalziel
Psychometric Properties of Child Health Utility 9D (CHU9D) Proxy Version Administered to Parents and Caregivers of Children Aged 2-4 Years Compared with Pediatric Quality of Life Inventory™ (PedsQL). PharmacoEconomics 42 (Suppl 1) (2024)
Mina Bahrampour, Renee Jones, Kim Dalziel, Nancy J Devlin, Brendan J Mulhern, null null
Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis. PharmacoEconomics 42 (Suppl 1) (2024)
Christine Mpundu-Kaambwa, Norma B Bulamu, Lauren Elizabeth Lines, Gang Chen, David G T Whitehurst, Kim Dalziel, Nancy J Devlin, Julie Ratcliffe, null null
Exploring the Use of Pictorial Approaches in the Development of Paediatric Patient-Reported Outcome Instruments: A Systematic Review. PharmacoEconomics 42 (Suppl 1) (2024)
Mina Bahrampour, Nancy J Devlin, Renee Jones, Kim Dalziel, Brendan J Mulhern, null null
A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Using Paediatric Multi-Instrument Comparison (P-MIC) Study Data. PharmacoEconomics 42 (Suppl 1) (2024)
Mina Bahrampour, Renee Jones, Kim Dalziel, Nancy J Devlin, Brendan J Mulhern, null null
Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis. PharmacoEconomics 42 (Suppl 1) (2024)
Diana Khanna, Jyoti Khadka, Christine Mpundu-Kaambwa, Gang Chen, Kim Dalziel, Nancy J Devlin, Julie Ratcliffe, null null
An Investigation of Inter-Rater and Intra-Proxy Agreement in Measuring Quality of Life of Children in the Community Using the EQ-5D-Y-3L. PharmacoEconomics 42 (Suppl 1) (2024)
Alexander van Heusden, Oliver Rivero-Arias, Michael Herdman, Harriet Hiscock, Nancy J Devlin, Kim Dalziel, null null
Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds. PharmacoEconomics 42 (Suppl 1) (2024)
Wendy J Ungar, Michael Herdman
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children. PharmacoEconomics 42 (Suppl 1) (2024)
Cate M Bailey, Kim Dalziel, Renee Jones, Harriet Hiscock, Nancy J Devlin, Tessa Peasgood, null null
The Validity of the EuroQol Health and Wellbeing Short Version (EQ-HWB-S) Instrument in Parents of Children With and Without Health Conditions. PharmacoEconomics 42 (Suppl 1) (2024)
Rachel O'Loughlin, Renee Jones, Gang Chen, Brendan J Mulhern, Harriet Hiscock, Nancy J Devlin, Kim Dalziel, null null
Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression. PharmacoEconomics 42 (Suppl 1) (2024)
Alexander van Heusden, Oliver Rivero-Arias, Michael Herdman, Harriet Hiscock, Nancy J Devlin, Kim Dalziel, null null
Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds. PharmacoEconomics 42 (Suppl 1) (2024)
Mina Bahrampour, Renee Jones, Kim Dalziel, Nancy J Devlin, Brendan J Mulhern, null null
Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis. PharmacoEconomics 42 (Suppl 1) (2024)
Mina Bahrampour, Nancy J Devlin, Renee Jones, Kim Dalziel, Brendan J Mulhern, null null
A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Using Paediatric Multi-Instrument Comparison (P-MIC) Study Data. PharmacoEconomics 42 (Suppl 1) (2024)

volume 42, number Suppl 2, 2024

Frederick McElwee, Anthony T Newall
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment. PharmacoEconomics 42 (Suppl 2) (2024)
Askal Ayalew Ali, Amit Kulkarni, Sandipan Bhattacharjee, Vakaramoko Diaby
Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework. PharmacoEconomics 42 (Suppl 2) (2024)
Frederick McElwee, Anthony T Newall
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment. PharmacoEconomics 42 (Suppl 2) (2024)
Meng Li, Louis P Garrison
Incorporating Real Option Value in Valuing Innovation: A Way Forward. PharmacoEconomics 42 (Suppl 2) (2024)
Richard Chapman, Richard Xie
Advancing Methods to Measure and Reward Healthcare Innovation. PharmacoEconomics 42 (Suppl 2) (2024)
Frederick McElwee, Anthony T Newall
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment. PharmacoEconomics 42 (Suppl 2) (2024)
Askal Ayalew Ali, Amit Kulkarni, Sandipan Bhattacharjee, Vakaramoko Diaby
Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework. PharmacoEconomics 42 (Suppl 2) (2024)
Richard Chapman, Richard Xie
Advancing Methods to Measure and Reward Healthcare Innovation. PharmacoEconomics 42 (Suppl 2) (2024)
Askal Ayalew Ali, Amit Kulkarni, Sandipan Bhattacharjee, Vakaramoko Diaby
Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework. PharmacoEconomics 42 (Suppl 2) (2024)
Richard Chapman, Richard Xie
Advancing Methods to Measure and Reward Healthcare Innovation. PharmacoEconomics 42 (Suppl 2) (2024)
Meng Li, Louis P Garrison
Incorporating Real Option Value in Valuing Innovation: A Way Forward. PharmacoEconomics 42 (Suppl 2) (2024)
Meng Li, Louis P Garrison
Incorporating Real Option Value in Valuing Innovation: A Way Forward. PharmacoEconomics 42 (Suppl 2) (2024)